ASH: Despite Novel Drugs In CML, Older Agents Are Tough To Dislodge

Superiority Data Vs. Generic Options

 
• By Alaric DeArment
  
(Alaric DeArment/Scrip)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from ASH

More from R&D